THREAD Acquires inVibe
THREAD, a technology and service provider enabling electronic clinical outcome assessments (eCOA) and decentralized clinical trials (DCTs), today announced that it has acquired inVibe, a voice-powered research and insights technology solution for the life sciences and health care industry.
Clinical trial sponsors and CROs can take advantage of the following new technology offerings and support services resulting from THREAD’s acquisition of inVibe:
- Integrated recruitment services that enable all health care stakeholders to participate in quantitative and qualitative research with minimal friction
- Technology to directly capture the actual voice of the participant and health care professionals to enhance research programs
- Analysis from trained linguists to leverage advanced natural language processing (NLP) software and voice analysis for experiences reported directly by the research patient
- Real-time data, dynamic dashboards, interactive listening sessions and reports with actionable insights, enabling immediate and informed decision-making
Read more about the acquisition here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
